Karyopharm Therapeutics reported $62.01M in Current Liabilities for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Acceleron Pharma XLRN:US $ 49.82M 10.34M
Amgen AMGN:US $ 12869M 1216M
Astrazeneca AZN:US $ 22222M 709M
AstraZeneca AZN:LN 22222M 709M
Avrobio Inc AVRO:US $ 12.77M 3.85M
Biocryst Pharmaceuticals BCRX:US $ 101.2M 4.45M
Bristol Myers Squibb BMY:US $ 18991M 1661M
Eli Lilly And LLY:US $ 11714.2M 767.4M
Enanta Pharmaceuticals ENTA:US $ 26.62M 3.57M
Epizyme EPZM:US $ 39.01M 4.39M
GlaxoSmithKline GSK:LN 21387M 1112M
Karyopharm Therapeutics KPTI:US $ 62.01M 1.8M
Macrogenics MGNX:US $ 69.92M 16.88M
Mirati Therapeutics MRTX:US $ 77.1M 5.63M
Nektar Therapeutics NKTR:US $ 123.63M 7.85M
Novartis NOVN:VX SF 30160M 2899M
Novartis NVS:US $ 29633M 527M
Regeneron Pharmaceuticals REGN:US $ 3217.8M 520.4M
Sangamo Biosciences SGMO:US $ 132.84M 10.71M
Takeda 4502:JP Y 1644766M 128410M
Xencor XNCR:US $ 99.93M 21.13M
YTE INCY:US $ 623.88M 7.31M